- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 491/08 - Bridged systems
Patent holdings for IPC class C07D 491/08
Total number of patents in this class: 675
10-year publication summary
|
61
|
40
|
39
|
60
|
49
|
42
|
64
|
63
|
50
|
29
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4729 |
20 |
| Merck Sharp & Dohme LLC | 3735 |
18 |
| Hoffmann-La Roche Inc. | 3783 |
15 |
| F. Hoffmann-La Roche AG | 7836 |
14 |
| Pfizer Inc. | 3384 |
14 |
| Amgen Inc. | 4425 |
14 |
| Vertex Pharmaceuticals Incorporated | 1584 |
13 |
| Epizyme, Inc. | 359 |
13 |
| Genentech, Inc. | 4099 |
12 |
| Merck Patent GmbH | 5725 |
12 |
| Zevra Therapeutics, Inc. | 99 |
10 |
| Novartis AG | 10263 |
8 |
| Rigel Pharmaceuticals, Inc. | 507 |
8 |
| Boehringer Ingelheim International GmbH | 4493 |
7 |
| Janssen Pharmaceutica N.V. | 3171 |
7 |
| Skyhawk Therapeutics, Inc. | 148 |
7 |
| Takeda Pharmaceutical Company Limited | 2715 |
6 |
| Bodor Laboratories, Inc. | 59 |
6 |
| Gilead Sciences, Inc. | 2220 |
6 |
| Kura Oncology, Inc. | 133 |
6 |
| Other owners | 459 |